Terns Announces $125M Raise Driven by Promising Oral GLP-1 Data

Tuesday, 10 September 2024, 07:34

Terns announces a $125 million offering on the heels of positive Phase I GLP-1 data. Analysts highlight its competitive positioning among leading obesity treatments. With plans for a Phase II trial, Terns aims to enhance its market presence.
LivaRava_Finance_Default_1.png
Terns Announces $125M Raise Driven by Promising Oral GLP-1 Data

Terns Announces $125M Raise Driven by Promising Oral GLP-1 Data

Terns Pharmaceuticals recently announced a $125 million public offering in response to encouraging Phase I data regarding its oral GLP-1 candidate, TERN-601. This candidate might rival established names like Eli Lilly, Pfizer, and Roche in the obesity treatment landscape.

Phase I Data: Promising Results

During the trial, participants using TERN-601 lost a mean weight of 4.9% after 28 days compared to placebo. This early-stage efficacy has garnered the attention of analysts, with Jefferies describing the results as surprisingly good. In comparison, Lilly's and Pfizer's candidates produced weight losses of 3.9% and 5.2%, respectively.

$125 Million Offering Details

  • Offering of $125 million in common stock
  • Option for an additional $18.75 million within 30 days
  • Funds to support Phase II trials and other company initiatives

Market Outlook

The weight loss market is predicted to expand significantly, potentially reaching between $100 billion and $160 billion over the next decade. Terns' focus on advancing its GLP-1 drug sets the stage for competitive interactions with giants like Roche, which is developing CT-966, another strong contender in the sector.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe